Merck advances with FDA breakthrough tag for cancer drug

Published 03/12/2024, 11:58
© Reuters.
MRK
-

Merck & Co (NYSE:MRK). Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to their investigational drug, sacituzumab tirumotecan (sac-TMT). This designation is for the treatment of certain patients with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) that exhibits epidermal growth factor receptor (EGFR) mutations, and who have undergone previous treatment.

The pharmaceutical giant is currently accelerating the global clinical development program for sac-TMT, which is being evaluated both as a standalone treatment and in combination with KEYTRUDA, Merck (NS:PROR)'s anti-PD-1 therapy. This development includes 10 ongoing Phase 3 studies targeting various solid tumors.

Sac-TMT has also marked a significant milestone internationally, having received its first marketing authorization in China. The National Medical (TASE:PMCN) Products Administration (NMPA) of China approved the drug for use in certain adults with unresectable locally advanced or metastatic triple-negative breast cancer who have already received at least two prior systemic therapies.

Kelun-Biotech, a biopharmaceutical company, retains the rights to develop, manufacture, and commercialize sac-TMT within the Greater China region. This recent FDA designation is expected to expedite the development and review of sac-TMT in the United States, given its potential to offer substantial improvement over existing therapies for serious or life-threatening diseases.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.